UT Southwestern NCI National Clinical Trials Network Lead Academic Site
UT 西南 NCI 国家临床试验网络领先学术网站
基本信息
- 批准号:10581694
- 负责人:
- 金额:$ 77.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-05-22 至 2025-02-28
- 项目状态:未结题
- 来源:
- 关键词:Academic Medical CentersAdministrative SupplementAdultAfrican AmericanAreaBasic ScienceBioinformaticsCancer CenterCategoriesClinicClinical InvestigatorClinical ResearchClinical TrialsClinical Trials NetworkColorectal CancerComprehensive Cancer CenterConduct Clinical TrialsCountryDiseaseEligibility DeterminationEnrollmentFacultyFundingGrantGrowthHealth ResourcesHispanicHospitalsImageInvestigational TherapiesLeadLeadershipMalignant NeoplasmsMalignant neoplasm of cervix uteriMalignant neoplasm of lungMedical centerMentorsNCI-Designated Cancer CenterNational Clinical Trials NetworkOutcomes ResearchPatient-Focused OutcomesPatientsPopulationPopulation HeterogeneityPopulation ResearchPositioning AttributeProcessPublicationsRaceRadioisotopesRecording of previous eventsRenal carcinomaResearchRoleSiteTexasTherapeuticTimeTranslatingUniversitiesbasecareer developmentclinical research siteclinical trial enrollmentcostdesigndrug discoveryethnic diversityethnic minorityinnovationmedical schoolsmembermetropolitannovelparticipant enrollmentpressureprogramsracial minorityscreeningtimeline
项目摘要
PROJECT SUMMARY/ABSTRACT
For years, the University of Texas Southwestern Medical Center (UTSW) has provided key leadership within
the National Clinical Trials Network (NCTN). The leaders of this UG1 application and other faculty members
hold major NCTN roles, including chairing clinical trials and committees. From March 2014 through August
2017, UTSW enrolled 520 patients on adult NCTN trials across 13 disease categories. During that time, UTSW
faculty authored or co-authored 27 publications directly related to NCTN trials, and have chaired, co-chaired, or
served as cooperative group committee chairs on 13 cooperative group trials. Substantial recent growth
positions UTSW to expand accrual and scientific contributions. After receiving initial NCI designation in 2010,
the Harold C. Simmons Cancer Center received comprehensive designation in 2015. Since 2015, two new
hospitals affiliated with UTSW have been constructed. We have a vibrant drug discovery program; SPORE
grants in lung cancer and kidney cancer; an Advanced Imaging Research Center; and a Patient Centered
Outcomes Research (PCOR) Center. As the only academic medical center and medical school in the
Dallas/Ft. Worth (DFW) Metroplex (population 7.2 million) and the only NCI-designated Comprehensive Cancer
Center in North Texas, UTSW reaches a large and diverse population that otherwise would not have access to
NCTN trials. In recent years, up to 29% of our patients enrolled on NCTN clinical studies were Hispanic, and
up to 21% were African American. The specific aims of the UTSW UG1 are the following: Aim 1. Contribute
to NCTN trial accrual. We will continue to enroll patients with diverse ethnic and racial backgrounds on
therapeutic and non-therapeutic trials. Aim 2. Contribute to NCTN scientific direction. We will bring UTSW
basic, translational, and imaging research into hypothesis-driven clinical trials. Aim 3. Provide NCTN
leadership. UTSW faculty will continue to chair and co-chair clinical trials and committees in the various
NCTN groups, and by participate in NCI activities and initiatives. Aim 4. Promote career development of
junior faculty and trainees. UTSW faculty will provide mentoring and guidance in the NCTN. Aim 5. Support
NCTN administrative efforts. UTSW faculty will continue to serve on NCTN and NCI regulatory and auditing
committees. At multiple steps, the design and conduct of cancer clinical research has become more
challenging. Financial pressures have limited the protected time of clinical investigators nationwide. Increasing
cost and complexity of clinical trials has prolonged activation timelines and restricted eligibility. UTSW is poised
to meet and overcome these challenges. With designated funding and mentoring programs, we continue to
develop clinical investigators and disease experts. We have capitalized on a large and diverse patient base, as
well as growing bioinformatics capabilities, to optimize the identification, screening, and enrollment of clinical
trial subjects. Together, these approaches position UTSW to continue to help lead and expand NCTN efforts.
项目摘要/摘要
多年来,德克萨斯大学西南医学中心(UTSW)在
国家临床试验网络(NCTN)。该UG1应用程序的负责人和其他教职员工
担任NCTN的主要职务,包括主持临床试验和委员会。2014年3月至8月
2017年,UTSW招募了520名患者参加13个疾病类别的成人NCTN试验。在此期间,UTSW
教职员工撰写或共同撰写了27篇与NCTN试验直接相关的出版物,并担任过主席、联合主席或
在13个合作组试验中担任合作组委员会主席。近期大幅增长
定位UTSW以扩大应计和科学贡献。在2010年收到初始NCI指定后,
哈罗德·C·西蒙斯癌症中心于2015年获得全面称号。自2015年以来,有两个新的
UTSW附属医院已经建成。我们有一个充满活力的药物发现计划;孢子
肺癌和肾癌的赠款;高级成像研究中心;以及以患者为中心
成果研究(PCOR)中心。作为全国唯一的学术医学中心和医学院
达拉斯/堡垒沃思(DFW)Metroplex(人口720万)和唯一被NCI指定为综合性癌症
位于德克萨斯州北部的UTSW中心,覆盖了大量多样化的人口,否则他们将无法获得
NCTN试验。近年来,参加NCTN临床研究的患者中,高达29%是西班牙裔,并且
高达21%的人是非裔美国人。UTSW UG1的具体目标如下:目标1.贡献
到NCTN试验应计费用。我们将继续招收不同民族和种族背景的患者
治疗性和非治疗性试验。目标2.为NCTN的科学方向做出贡献。我们将带来UTSW
以假设为导向的临床试验的基础研究、转化研究和成像研究。目标3.提供NCTN
领导力。UTSW的教职员工将继续担任各种临床试验和委员会的主席和联合主席
NCTN团体,并通过参与NCI活动和倡议。目标4.促进职业发展
初级教职员工和实习生。UTSW的教职员工将在NCTN提供指导和指导。目标5.支持
NCTN的管理努力。UTSW教员将继续在NCTN和NCI监管和审计部门任职
委员会。在多个步骤中,癌症临床研究的设计和实施已变得更加
很有挑战性。财政压力限制了全国临床研究人员的保护时间。渐增
临床试验的成本和复杂性延长了激活时间,限制了资格。UTSW已做好准备
迎接和克服这些挑战。通过指定的资金和指导计划,我们将继续
培养临床研究人员和疾病专家。我们利用了庞大而多样化的患者基础,如
以及不断增长的生物信息学能力,以优化临床患者的识别、筛选和登记
受试者。总而言之,这些方法使UTSW能够继续帮助领导和扩大NCTN的努力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
David Eric Gerber其他文献
David Eric Gerber的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('David Eric Gerber', 18)}}的其他基金
Finding the optimal balance of immunotherapy efficacy and toxicity.
寻找免疫治疗功效和毒性的最佳平衡。
- 批准号:
10630125 - 财政年份:2020
- 资助金额:
$ 77.96万 - 项目类别:
Finding the optimal balance of immunotherapy efficacy and toxicity.
寻找免疫治疗功效和毒性的最佳平衡。
- 批准号:
10418693 - 财政年份:2020
- 资助金额:
$ 77.96万 - 项目类别:
Finding the optimal balance of immunotherapy efficacy and toxicity.
寻找免疫治疗功效和毒性的最佳平衡。
- 批准号:
9921601 - 财政年份:2020
- 资助金额:
$ 77.96万 - 项目类别:
Finding the optimal balance of immunotherapy efficacy and toxicity.
寻找免疫治疗功效和毒性的最佳平衡。
- 批准号:
10376977 - 财政年份:2020
- 资助金额:
$ 77.96万 - 项目类别:
Finding the optimal balance of immunotherapy efficacy and toxicity.
寻找免疫治疗功效和毒性的最佳平衡。
- 批准号:
10189523 - 财政年份:2020
- 资助金额:
$ 77.96万 - 项目类别:
UT Southwestern NCI National Clinical Trials Network Lead Academic Site
UT 西南 NCI 国家临床试验网络领先学术网站
- 批准号:
10359155 - 财政年份:2019
- 资助金额:
$ 77.96万 - 项目类别:
UT Southwestern NCI National Clinical Trials Network Lead Academic Site
UT 西南 NCI 国家临床试验网络领先学术网站
- 批准号:
10062108 - 财政年份:2019
- 资助金额:
$ 77.96万 - 项目类别:
UT Southwestern NCI National Clinical Trials Network (NCTN) LAPS - Supplemental Funds YR4
UT 西南 NCI 国家临床试验网络 (NCTN) LAPS - 补充资金 YR4
- 批准号:
10733732 - 财政年份:2019
- 资助金额:
$ 77.96万 - 项目类别:
Evaluating prior cancer exclusion policy to increase lung cancer trial accrual
评估先前的癌症排除政策以增加肺癌试验的应计数量
- 批准号:
9108931 - 财政年份:2015
- 资助金额:
$ 77.96万 - 项目类别:
UT Southwestern NCI National Clinical Trials Network Lead Academic Site - U10
UT 西南 NCI 国家临床试验网络主要学术网站 - U10
- 批准号:
9248972 - 财政年份:2014
- 资助金额:
$ 77.96万 - 项目类别:
相似海外基金
A Longitudinal Qualitative Study of Fentanyl-Stimulant Polysubstance Use Among People Experiencing Homelessness (Administrative supplement)
无家可归者使用芬太尼兴奋剂多物质的纵向定性研究(行政补充)
- 批准号:
10841820 - 财政年份:2023
- 资助金额:
$ 77.96万 - 项目类别:
Proton-secreting epithelial cells as key modulators of epididymal mucosal immunity - Administrative Supplement
质子分泌上皮细胞作为附睾粘膜免疫的关键调节剂 - 行政补充
- 批准号:
10833895 - 财政年份:2023
- 资助金额:
$ 77.96万 - 项目类别:
Administrative Supplement: Life-Space and Activity Digital Markers for Detection of Cognitive Decline in Community-Dwelling Older Adults: The RAMS Study
行政补充:用于检测社区老年人认知衰退的生活空间和活动数字标记:RAMS 研究
- 批准号:
10844667 - 财政年份:2023
- 资助金额:
$ 77.96万 - 项目类别:
StrokeNet Administrative Supplement for the Funding Extension
StrokeNet 资助延期行政补充文件
- 批准号:
10850135 - 财政年份:2023
- 资助金额:
$ 77.96万 - 项目类别:
2023 NINDS Landis Mentorship Award - Administrative Supplement to NS121106 Control of Axon Initial Segment in Epilepsy
2023 年 NINDS 兰迪斯指导奖 - NS121106 癫痫轴突初始段控制的行政补充
- 批准号:
10896844 - 财政年份:2023
- 资助金额:
$ 77.96万 - 项目类别:
Biomarkers of Disease in Alcoholic Hepatitis Administrative Supplement
酒精性肝炎行政补充剂中疾病的生物标志物
- 批准号:
10840220 - 财政年份:2023
- 资助金额:
$ 77.96万 - 项目类别:
Administrative Supplement: Improving Inference of Genetic Architecture and Selection with African Genomes
行政补充:利用非洲基因组改进遗传结构的推断和选择
- 批准号:
10891050 - 财政年份:2023
- 资助金额:
$ 77.96万 - 项目类别:
Power-Up Study Administrative Supplement to Promote Diversity
促进多元化的 Power-Up 研究行政补充
- 批准号:
10711717 - 财政年份:2023
- 资助金额:
$ 77.96万 - 项目类别:
Administrative Supplement for Peer-Delivered and Technology-Assisted Integrated Illness Management and Recovery
同行交付和技术辅助的综合疾病管理和康复的行政补充
- 批准号:
10811292 - 财政年份:2023
- 资助金额:
$ 77.96万 - 项目类别:
Administrative Supplement: Genome Resources for Model Amphibians
行政补充:模型两栖动物基因组资源
- 批准号:
10806365 - 财政年份:2023
- 资助金额:
$ 77.96万 - 项目类别: